The authors of this consensus statement look at the history of the use of the Abnormal Involuntary Movement Scale in tardive dyskinesia studies and outline the challenges of using AIMS results in clinical practice. They then propose different methods for reporting AIMS data that may provide broader and more clinically relevant perspectives.
Vitamin E is one of many antioxidants used for the treatment of tardive dyskinesia. It has been suggested that long-term vitamin E therapy may increase risk for prostate cancer, which is concerning given that high doses are used to treat tardive dyskinesia. Read this case report to find out more about this important topic.
Valbenazine, a VMAT2 inhibitor, is approved for the treatment of tardive dyskinesia. However, its long-term safety and efficacy have not been reported. This extension of the KINECT 3 study examined outcomes of valbenazine treatment over a 42-week period. Did the medication maintain its tolerability, safety, and effects on tardive dyskinesia symptoms?
Can switching antipsychotic type or changing the dose reduce the symptoms of parkinsonism and tardive dyskinesia? Review the drug effects with changes in high and low dopamine-2 affinity in 223 patients over an 18-year period.
With the advent of second-generation antipsychotics, hopes were high that tardive dyskinesia would all but disappear as a side effect. However, it persists. In this meta-analysis, Carbon et al analyze 41 studies to determine how prevalent tardive dyskinesia still is during treatment with first-generation and/or second-generation antipsychotics.
Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit
To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be particularly useful in patients with liver disease,” deserves comment.1
First, Andrade failed to recall that the first pivotal trial of baclofen, ALPADIR (NCT01738282; 320 patients, as with Bacloville), was negative (see Braillon et al2).
Second, Dr Andrade should have warned readers that Bacloville’s results are most questionable, lacking robustness. Although he cited us,3 he overlooked the evidence we provided indicating that the Bacloville article4 was published without acknowledging major changes to the initial protocol, affecting the primary outcome. Coincidentally (although as skeptics, we do not believe in coincidence), the initial statistical team was changed when data were sold to the French pharmaceutical company applying for the marketing authorization in France. As Ronald H. Coase warned, “If you torture the data long enough, it will confess.”